Epigenomics in Hurthle Cell Neoplasms: Filling in the Gaps Towards Clinical Application

Sule Canberk1,2,3†, Ana Rita Lima1,2,4†, Mafalda Pinto1,2, Paula Soares1,2,4,5 and Valdemar Máximo1,2,4,5*

1 Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal, 2 Cancer Signaling and Metabolism Group, Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal, 3 Abel Salazar Institute of Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal, 4 Faculty of Medicine, University of Porto (FMUP), Porto, Portugal, 5 Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal

It has been widely described that cancer genomes have frequent alterations to the epigenome, including epigenetic silencing of various tumor suppressor genes with functions in almost all cancer-relevant signalling pathways, such as apoptosis, cell proliferation, cell migration and DNA repair. Epigenetic alterations comprise DNA methylation, histone modification, and microRNAs dysregulated expression and they play a significant role in the differentiation and proliferation properties of TC. In this review, our group assessed the published evidence on the tumorigenic role of epigenomics in Hurthle cell neoplasms (HCN), highlighting the yet limited, heterogeneous and non-validated data preventing its current use in clinical practice, despite the well developed assessment techniques available. The identified evidence gaps call for a joint endeavour by the medical community towards a deeper and more systematic study of HCN, aiming at defining epigenetic markers in early diagnose, allowing for accurate stratification of malignancy and disease risk and for effective systemic treatment.

Keywords: thyroid tumors, Hürthle cells, oncocytic cells, mitochondria, epigenomics, epigenetics analysis, Hürthle cell tumors, Hürthle cell carcinoma

INTRODUCTION

What are Hürthle Cell Tumors?

Only a few neoplasms have been gaining so many names in their history as oncocytic thyroid neoplasms, reflecting the uncertainty about their nature: Askanazy cell tumor, oxyphilic cell tumor, Langhan’s Struma, Baber cell tumor, Getzowa’s Struma, Hürthle cell tumor, oncocytic cell tumor, among others (1). In 2004, the 3rd edition of the World Health Organization (WHO) Classification of Tumors endorsed the term “oncocytic tumors”, instead of “Hürthle cell tumors”, to clarify that 75% of oncocytces were classified as a variant under the category of papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) (2). The 4th edition of the WHO Classification of Tumors establishes a new tumor entity under the title of Hürthle cell neoplasms (HCN) (3). The unifying feature in those tumors is the cytoplasmatic enrichment in mitochondria (from several hundreds to thousands), that gives the characteristic acidophilic, granular aspect to oncocytces.
Hürthle cell neoplasms (HCN) are rare in comparison with non-oncocytic follicular cell-derived neoplasms, with variable incidence and prevalence in different studies. According to the 4th edition of the WHO Classification of Tumors (3), there are two types of HCN: Hürthle cell adenoma (HCA) and Hürthle cell carcinoma (HCC), both composed by 75% or more of Hürthle cells (2). The presence or absence of invasion into the tumor capsule and vessel (angio) distinguishes HCA from HCC. Similar to FTCs, HCCs are classified as minimally invasive, encapsulated angioinvasive and widely invasive (2).

HCCs are referred to as poorly radioiodine avid and poorly responsive to chemotherapy and radiation. Outcomes of patients with widely invasive HCC are poorer compared with patients with minimally invasive HCC (3–6). Despite their unique morphology and molecular background, no well-defined molecular markers exist in daily practice for HCC. This becomes more of an unmet need not only in the diagnose, but also for the treatment of these tumors. Indeed, HCC corresponds to 3% to 7% of all differentiated thyroid cancers, but ranges from 10.5% to 43% in recurrent cases, which highlights the unmet need for effective treatment strategies (4–7).

**What Is Epigenetics?**

Epigenetics means “beyond genetics,” and it represents diverse mechanisms that modify both gene expression and genome stability without affecting the DNA sequence itself. The term “epigenetics” was first coined by Waddington in the early 1940s (8). He described the term as the “causal interactions between genes and their products, which bring the phenotype into being” (8). After many advances achieved over decades, this eloquent description still faithfully describes the main characteristic of epigenetics: phenotype changes in gene expression, which are not related with changes in the DNA sequence both in mitosis and between generations. The effects of epigenetical mechanisms on DNA are not “additional” or “contrary” to genetical mechanisms, but are manifested by an interplay between genetic and epigenetic mechanisms on the roadmap to cancer transformation.

Gene transcription strongly depends on the chromatin structure: in general, the “switch on” or open/decondensed (euchromatin) states are transcriptionally active, whereas the “switch off” or close/condensed (heterochromatin) states are transcriptionally inactive. This continuous interaction between the chromatin remodelling processes is currently denominated “epigenome” – the epigenetic status that determines the way a single eukaryotic genome may manifest itself in different cell types and developmental stages and which, if aberrant, give rise to cancer and other diseases (9). These conformational changes of epigenetic regulation that may cause mitotically and/or meiotically inheritable changes in gene function, without entailing any change in DNA sequence, can be classified into three distinct types: DNA methylation, histone modifications, and non-coding ribosomal RNAs (rRNAs) (Figure 1) (9–11). Each of these epigenetic pathways involves enzymes that transfer the modification (‘writers’), enzymes that modify or revert a modification (‘erasers’), and enzymes that mediate the interactions of proteins or protein complexes with the modification (‘readers’) (12). It is well-known that cancer genomes show frequent alterations of the epigenome, including epigenetic silencing of various tumor suppressor genes with functions in almost all cancer-relevant signalling pathways, such as apoptosis, cell proliferation, cell migration and DNA repair (12).

Epigenetic alterations also play a highly significant role in the differentiation and proliferation properties of thyroid carcinoma (TC) (11, 12). In this review, our group covers the role of epigenomics in the HCN, along with the main epigenetic mechanisms and potential therapy application of epigenetic targeted therapies in HCC.

**Molecular Techniques for the Analysis of Epigenetic Alterations**

Epigenetic alterations, such as DNA methylation and histone modification, as well as microRNAs dysregulated expression, may serve as biomarkers for early detection, disease classification and risk stratification, as well as targets for therapy and chemoprevention.

Numerous techniques have been developed to explore the epigenetic processes, not only at gene level but also genome-wide. Those techniques are widely applied to pathology samples, such as formalin-fixed paraffin-embedded (FFPE) tissues or cytology samples, out of which bisulphite modification of DNA and chromatin immunoprecipitation outline the basis for tracking DNA methylation changes and chromatin modifications, respectively. For microRNA expression alterations, quantitative reverse transcription polymerase chain reaction (qRT-PCR) is normally the elected technique (Figure 2).

**DNA Methylation in Hürthle Cell Tumors**

CpG islands are short stretches of DNA encompassing high GC content and CpG dinucleotides (cytosine 5’ to a guanine, separated by a phosphodiester bond) in comparison with the rest of the genome. CpG islands account for about 1–2% of the genome and are usually located in the 5’ regulatory region of genes. CpG nucleotides are detected in a lower than expected proportion based on the G/C content, and are not homogenously distributed throughout the human genome. CpG islands are regions of human genome rich in GC content that include the promoters of 60% of protein coding genes. In humans, DNA methylation occurs most often in CpG islands, and is frequently localized close to promoters of housekeeping genes and in up to 40% of tissue specific genes (13, 14). In general, methylated CpG islands have been correlated with the transcriptional silencing of the associated genes and non-coding genomic regions, although there are exceptions. Thus, DNA methylation is frequently known as a major repressive epigenetic mark. Nevertheless, DNA methylation function varies with the genomic context (15, 16). If DNA methylation takes place in proximal and distal regulatory elements (i.e., promoters and enhancers, respectively), it represses transcription by affecting the binding of transcription factors and/or recruiting enzymes that modify chromatin structure. However, DNA methylation of the gene body may enhance transcriptional elongation and affect splicing. Therefore, DNA methylation is a key player in the regulation of gene expression, and it has been implicated in many cellular
processes, such as imprinting (17, 18), X-chromosome inactivation (19), and the establishment and maintenance of cell type-specific expression programs. In other words, the hypermethylation of the CpG islands in promoter regions, which has been commonly detected in cancer cells, usually leads to the silencing of tumor suppressor genes, whereas the global hypomethylation of DNA has been more frequently reported in association with tumor progression. This pattern of global hypomethylation and regional hypermethylation, might play a pivotal role in human carcinogenesis (20).

DNA methylation is catalysed by a family of DNA methyltransferases (DNMTs) that transfer a methyl group
from S-adenyl methionine (SAM) to the fifth carbon of a
pyrimidine residue to form 5mC; DNMT1 maintains the DNA
methylation pattern from the parental DNA strand in the newly
synthesized daughter and is capable of repairing DNA
methylation, whereas DNMT3a and DNMT3b can harbor a
new methylation pattern without requiring hemi-methylated
DNA, thus naming this process as “de novo” DNMT. These
two types of methylation patterns are known as “active” and
“de novo”, respectively, and both contribute to the (im)balance
of the roadmap which may lead to tumorigenesis (21). Cancer
genome is typically characterized by global hypomethylation
concomitantly with hypermethylation of CpG islands in the
promoters of genes that play important roles in regulating cell
cycle, apoptosis, differentiation, and cell adhesion (9).

Nowadays, DNA methylation has been gaining attraction for its
important wellspring of promising cell-type specific cancer
biomarkers, especially since there is yearslong protecting stability
of DNA methylation, even in formalin-fixed samples, which makes
it easily detectable by well-established techniques (Figure 1),
including in cytology materials (1-4).

There has been a limited number of DNA methylation
studies of TC in the literature, and most of them were focused
on PTC. The Cancer Genoma Atlas (TCGA) analysed the
methylation profiles of 496 cases of TC using a high-density
platform (Illumina HumanMethylation EPIC bead array), and suggested a
classification based on the genomic profiles, which would support
a rational patient disease management (20, 22). However, when
it comes to HCN, the literature available is even more limited
(Table 1). One explanation for this is that these neoplasms were
classified as a variant of FTA/FTC and many of the studies
were designed before the 4th edition of the WHO Classification
of Tumors. Also, it is possible that the fact that no differences
on the global methylation of cytosine were found between HA
and FTA by Galusca et al. (23) led to a lack of interest in new
studies in this field. Galusca et al. designed a study based on
immunohistochemistry of benign and malignant thyroid
neoplasms including ten Hürthle cell adenomas (HA) (23). The
authors concluded that benign tumors (FA or HA and MNG) had
a significant higher global DNA methylation level than the
studied TC cases (P<0.001) (23). The analyses of benign lesions
(hyperplasia, FA and HA) did not find differences between
benign lesions and normal thyroid tissues. These results are
in line with those previously published concerning 5-
methylcytidine level in lung cancers cells (31, 32), breast
carcinoma (33) or colorectal adenocarcinomas (34) where no
differences where found in relation to the surrounding normal
tissues (35).

One of the recent studies by Park et al. (24), which was
designed after the 4th edition of the WHO Classification of
Tumors (3), quantitatively profiled the genome-wide DNA
methylation in a group of thyroid tumors by means of the
Illumina HumanMethylation EPIC bead array. Using a cohort
comprising 24 HA and 5 HCC alongside with PTC, FTC and
non-invasive follicular thyroid neoplasm with papillary-like
nuclear features (NIFTP) cases, the authors verified a
statistically significant hypomethylation of three specific marks
- cg10705422, cg17707274, and cg26849382 - in malignant
tumors. They also found that in this tumor group the three
marks were significantly associated with recurrent or persistent
disease. The authors concluded that DNA methylation levels of
those three markers could be a promising novel diagnostic/
prognostic biomarker for well-differentiated thyroid cancer
(WDTC). Considering that alterations in DNA methylation
play a role in tumorigenesis and disease progression, these
DNA methylation markers may be clinically useful for
stratifying thyroid tumors in a more efficient way (24).

Braït et al. (25) also evaluated BRAF mutation and promoter
dNA methylation for 22 selected cancer-related genes, in a
group of thyroid malignant and benign cases, including 12 HA
and 2 HCC, in comparison with adjacent normal thyroid. The
relevance of the upregulation of the RAF/MEK/MAPK kinase
pathway in TC, either by a BRAF activating mutation or
RASSF1A methylation (hypermethylation mutually exclusive
with BRAF mutation) silencing, was further confirmed by this
study, without any difference between Hürthle non-Hürthle
morphology. Previously, hypermethylation of tumor suppressor
gene RASSF1A was reported in 75% (9 of 12) of FTCs, as well as
in a smaller percentage of benign adenomas (44%), and PTCs
(20%) (36), indicating that this may represent an early step in
follicular cell-derived thyroid tumorigenesis. Following this
hypothesis, Stephen et al. (26) examined the promoter
hypermethylation of 24 tumor suppressor genes using the
methylation-specific multiplex ligation-dependent probe
amplification (MS-MLPA) assay, as well as that of Na-I
symporter (NIS) gene using methylation-specific PCR (MSP).
In a pilot study of 21 thyroid cases, including normal thyroid
tissue and benign thyroid lesions, FTC and anaplastic thyroid
carcinoma (ATC), 2 cases of FTC (one of them formerly named
as an oncocytic variant of FTC, now known as HCC). They have
concluded that RASSF1, CASP8 and NIS were frequently
methylated in their promoters, which may indicate a role in
early tumorigenesis, regardless of the cell type (26).

In 2015, again Stephen et al. (27) analysed retrospectively
the promoter methylation status in a cohort of 26 HCC and 27
FTCnbspcases, both in comparison with each other and with
their adjacent normal tissues. The group found that RASSF1

demonstrates a significant differential methylation between FTC-
Classic and FTC-Hurthle, with higher methylation levels in FTC-
Classic (P<0.01), suggesting its use as a molecular marker to
differentiate these two subtypes. Comparisons with their matching
adjacent normal tissues were also significant (P=0.01) (26).

Bisarro Dos Reis et al. (28) performed an unsupervised
clustering analysis of the genome-wide DNA methylation profiles
in a series of thyroid tumors. Although HCCs were not separated
from FTCs, the FTC/HCC group clustered together with the ATC/
poorly differentiated thyroid carcinoma (PDTC) group and with
lymphocytic thyroiditis. This cluster showed major alterations in
genes related to immune response. Of note, the FTC/HCC group
showed hypermethylation in approximately 3/4 of all identified
probes differentially methylated (28).

Ganly et al. (29) recently found that mutations in genes
encoding for chromatin and DNA modifying enzymes are
| Sample size | DNA methylation | Molecular alterations | Methods | Reference |
|-------------|----------------|----------------------|---------|-----------|
| 16 FA, 10 HA, 19 MNG, 17 PTC, 6 FTC | Lower level of 5-mC immunostaining in TC versus benign tumors or adjacent normal thyroid parenchyma ($P<0.0001$) | Immunohistochemistry | Galusca et al. (23) |
| 61 FA, 56 NIFTP, 120 PTC, 27 FTC, 5 HCC | Hypomethylation of cg10705422, cg17707274, and cg28849382 differentiated nonmalignant (FA, HA, and NIFTP) tumors from differentiated TC | Illumina HumanMethylation EPIC bead array and pyrosequencing | Park et al. (24) |
| 24 HA, 56 NIFTP, 120 PTC, 27 FTC, 5 HCC | Increased KIF1A probability of methylation in tumor samples (14% in cancer tissue versus 0% in normal and benign; $P = 0.02$) | Quantitative methylation specific PCR (Q MSP) | Brait et al. (25) |
| 12 FA, 19 MNG, 1 multinodular hyperplasia, 12 HA, 6 AN, 1 AH, 6 HN, 6 MNG, 1 multinodular hyperplasia, 12 HA, 27 PTC, 7 FTC, 2 HCC, 8 FTC, 5 NTS, 3 hyperfunctioning nodules, 11 PTC, 1 FTC, 1 HCC | Increased RASSF1A methylation levels in cancer versus benign samples ($P = 0.05$) | Methylation specific multiplex ligation-dependent probe amplification (MS-MLPA) assay for 24 tumor suppressor genes and methylation-specific PCR (MSP) for NIS gene | Stephen et al. (26) |
| - 3/3, 2/3 and 1/3, respectively, in hyperthyroid samples | Negative univariate correlation between BRAF mutation and RASSF1A methylation ($P = 0.035$) | Methylation specific multiplex ligation-dependent probe amplification (MS-MLPA) assay for 24 tumor suppressor genes and methylation-specific PCR (MSP) for NIS gene | Stephen et al. (26) |
| - 9/13, 10/13, and 7/13 respectively, in TC | Positive univariate correlation between BRAF mutation and methylation of RARβ2 ($P = 0.05$), TIMP3 ($P = 0.05$) and DCC ($P = 0.01$) | Methylation specific multiplex ligation-dependent probe amplification (MS-MLPA) assay for 24 tumor suppressor genes and methylation-specific PCR (MSP) for NIS gene | Stephen et al. (26) |
| - 3/11, 4/11 and 3/11, respectively, TC cases matched with normal thyroid tissue | Cluster 1: enriched with FAs, nodular goiters, and minimally invasive FTCs, showing more frequent hypermethylation events; enriched by signal transduction–related genes | Methylation specific multiplex ligation-dependent probe amplification (MS-MLPA) assay for 24 tumor suppressor genes and methylation-specific PCR (MSP) for NIS gene | Stephen et al. (26) |

(Continued)
frequent, with 59% of the 56 studied HCC cases harbouring such mutations.

Finally, it is noteworthy the contribution of Weber et al. (30) for the understanding of the carcinogenesis of FTC when they showed that the tumor suppressor gene aplayia ras homolog I (ARHI) was frequently underexpressed in FTCs, even in minimally invasive tumors, including 6 oncocyctic variants (P = 0.0018), as compared to PTC or FA. Based on their studies, the authors have suggested that silencing of the putative maternal imprint tumor suppressor gene ARHI, primarily by large genomic deletion associated with hypermethylation of the genomically imprinted allele, is an important event in follicular thyroid carcinogenesis.

**Histone Modification in Hürthle Cell Tumors**

DNA is associated with histone proteins to form a condensed structure known as chromatin. Chromatin encompasses 147 bp of DNA bundling up an octamer of four histone proteins (H2A, H2B, H3, and H4) (37). Histone modifications can go through various types of post-translational changes, including methylation, acetylation, phosphorylation and ubiquitination, and these may modulate gene silencing concomitantly with DNA promoter methylation (17, 38). In general, acetylation of histones, such as H3 and H4, and methylation of the lysine-4 residue of histone H3 (H3K4) are associated with transcriptional activation and active genes (39, 40). Deacetylation, on the other hand, is associated with gene silencing of tumor suppressor genes in the carcinogenesis process (40, 41). Methylated DNA recruits methyl-binding proteins (MBDPs), which have methyl-CpG-binding domains (MBD), to hypermethylated DNA. MBDPs associate with histone deacetylases, resulting in chromatin remodeling and gene silencing. In addition to these mechanisms of silencing, histone methyltransferase (HMTs) repress transcription by methylation of lysine 9 of histone 3 (H3K9) or lysine 27 of histone 3 (H3K27) (40). As mentioned before, epigenetic modifications can go through as common events in genes of HCC encoding thyroid genes (39, 40).

### TABLE 1 | Continued

| Sample size | Molecular alterations | Methods | Reference |
|-------------|----------------------|---------|-----------|
| 56 HCC      | Mutations in 59% of tumors [53/56]: A. Chromatin-modifying complexes - SWI/SNF, ISWI/CHD, and INO80 families - ARID1A (4%), CHD2, 4, 5, 8, 9, and H (12%) - Histone acetyltransferase (CREBBP [5%] and BRD7 [7%]) - Histone methyltransferases (KMT2C [5%], NSD1 [4%], and EZH1 [4%]) - Histone deacetylases (HAT7 [2%] and SIRT6 [2%]) - Histone demethylases (PHF2 [4%] and KDM2B, 4C, and 5C [6%]) - Histones (HIST1H1E [2%] and HIST1H3D [2%]) B. DNA modifiers (9% [6/56 tumors]): - DNMT1 [2%] and DNMT3A [2%] - DNA demethylases (TET1 [2%] and TET2 [5%]) ARHI underexpression in FTC, including six oFTC versus FAs, (P = 0.0018) | Whole exome sequencing (WES) | Ganly et al. (29) |
| 5 NTS, 14 FA, 11 FTC, 6 HCC | ARHI underexpression in all minimally invasive FTC (2 classic FTC and 2 HCC) | Real-time quantitative polymerase chain reaction (RT-PCR) | Weber et al. (30) |
| 7 PTC | ARHI underexpression in FTC versus normal thyroid tissue (P = 0.022) or FAs (P = 0.0091) | Sodium bisulfite genomic sequencing | Quantitative PCR (qPCR) |
| 56 HCC modifications | Mutations in histone acetyltransferases (CREBBP [5%] and BRD7 [7%]), histone methyltransferases (KMT2C [5%], NSD1 [4%], and EZH1 [4%]), histone deacetylases (HAT7 [2%] and SIRT6 [2%]), histone demethylases (PHF2 [4%] and KDM2B, 4C, and 5C [6%]), and histones (HIST1H1E [2%] and HIST1H3D [2%]) | Whole exome sequencing (WES) | Ganly et al. (29) |

FA, follicular adenoma; HA, Hürthle cell adenoma; MNG, multiodular goiter; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; NIFTP, non-invasive follicular thyroid neoplasm with papillary-like nuclear features; HCC, Hürthle cell carcinoma; HN, hyperplastic nodule; NTS, normal thyroid specimens; AH, adenomatoid hyperplasia; MTC, medullary thyroid carcinoma; PDTC, poorly differentiated thyroid carcinoma; ATC, anaplastic thyroid carcinoma; oFTC, oncocytic variant of follicular thyroid carcinoma.
demethylases (PHF2 [4%] and KDM2B, 4C, and 5C [6%]), and histones (HIST1H1E [2%] and HIST1H3D [2%]) (29).

**RNA-Associated Silencing in Hürthle Cell Tumors**

MicroRNAs (mi-RNAs) are small (19–23, 31, 32) non-coding RNAs, which control gene expression through post-transcriptional regulation of various cellular processes, such as differentiation, proliferation and apoptosis (44). Signatures associated with their expression have been related to diagnosis, staging, prognosis, and response to treatment in human tumors (45–47). Changes in mi-RNA expression are involved in carcinogenesis and tumor progression, through downregulation of tumor suppressor genes and/or upregulation of oncogene (48–51). One of the first pivotal series which characterized the miRNA expression profile of different benign and malignant thyroid neoplasms, including HA and HCC, was published by Nikiforov et al. (52). The ten most up-regulated miRNAs in HA when compared with normal thyroid tissue were, respectively from higher to lower, miR-31, miR-339, miR-183, miR-182, miR-181b, miR-221, miR-96, miR-182, miR-224 and miR-203. In comparison with thyroid hyperplastic tissue, miR-31, miR-339, miR-183, miR-221 and miR-203 were significantly more expressed in HA. In HCC, the ten most up-regulated miRNAs were miR-187, miR-221, miR-339, miR-183, miR-222, miR-181b, miR-182, miR-213, miR-96, miR-197, respectively from higher to lower levels. miR-187, miR-221, miR-339, miR-183, miR-222, and the miR-197 were significantly more expressed when compared with hyperplastic thyroid tissue. Interestingly, within the adenoma group, non-oncotic tumors expressed a pattern of miRNA different from that of HA. Indeed, miR-200a was the most expressed miRNA in HA and miR-31 was the most expressed in HCC. A cluster analysis showed that clusters of miRNA expression in HCN are different from those of non-oncotic tumors, which supports the theory that HCN represent a unique class of thyroid tumors, as opposed to a subgroup of follicular-derived tumors (2). The evidence that a cluster of identical miRNAs is present in both benign and malignant follicular tumors with Hürthle cell characteristics supports the assumption that these represent a phenotype that is superimposed on different oncogenic genotypes (53). Vriens et al. (54) found that four of ten miRNAs, initially mapped by a miRNA array, were significantly and differentially expressed when comparing benign and malignant thyroid neoplasms by real-time quantitative polymerase chain reaction (RT-qPCR). In particular, miR-100, miR-125b, miR-138, and miR-768-3p were found to be overexpressed in malignant follicular tumors and in HCC samples when compared with HA (54). The accuracy for distinguishing benign from malignant HCN was 98% (miR-138 and miR-768-3p) (54). Dettmer et al. (55) assessed the difference in miRNA expression between PDTC and WDPTC using PCR-Microarrays. In this study, they found that the oncotic variant of PDTC (oPDTC) presented an upregulation of miR-221 and miR-885-5p when compared with the non-oPDTC (55). When oPDTC were compared with HCC, there was a loss of expression of miR-125a-5p, -183-3p, -219-5p, -221 and miR-885-5p. In addition, miR-222 was twice more expressed in oPDTC compared with HCC (55). Petric et al. (56) assessed whether there was any miRNA which could be predictive of metastases in HCC, based on a series of 39 patients, and using TaqMan miRNA assays targeting six miRNAs (miR-138, miR-183, miR-221, miR-222, miR-768-3p, and miR-885-5p). These authors found that miR-138 and miR-768-3p were significantly downregulated in HCC tumor samples, as well as in patients with metastatic disease, but not in patients with non-metastatic disease, in comparison with normal tissue (56). In tumors of patients without metastases, miR-221 and miR-885-5p were significantly upregulated when compared with normal tissue. When the difference of miRNA expression in tumor versus normal tissue was compared between patients with and without metastases, miR-183, miR-221, and miR885-5p were significantly downregulated in patients with metastases, suggesting that the expression of miR-183, miR-221, and miR-885-5p in tumor tissue is inversely correlated with the risk of distant metastases in patients with HCC (56). A study by Covach et al. (57), which assessed metastases associated lung adenocarcinoma transcript 1 (MALAT1) and miR-RNA-885-5p through in situ hybridization (ISH) found that MALAT1 was more highly expressed in HCCs compared with FTCs, although the differences were not statistically significant (P= 0.06). Likewise, miR-885 expressed in similar levels in FTCs and HCCs. Jacques et al. (58) reported the results of transcriptomic analysis, which led to the identification of 13 genes allowing the discrimination between thyroid adenomas, HA/HCC and PTC. The overall miRNA analysis revealed 10 differently expressed miRNAs, whose levels were confirmed by qPCR (58). In their study, TP53 and RUNXI were the main genes regulated by the selected miRNAs, which proved to play a role in thyroid tumor development and differentiation. The targeted assay tested by these authors allowed the specific investigation of thyroid mitochondrial metabolism and tumorigenesis genes, which are partially regulated by miRNAs. In this study, mitochondrial metabolism of HA/HCC appeared to differ from that of PTC, suggesting metabolic variations of the organelle in these two tumor types (58) (Table 2).

**Hürthle Cell Tumors and Epigenetic Therapy**

Previous studies have suggested that patients with HCC should be treated as non-HCC patients with equivalent tumor staging (59). Specific recommendations for the treatment of HCC are lacking (60), and the management of HCC tends to be similar to that of FTC, acknowledging two particular characteristics: locoregional lymph node and distant metastases are more frequent, and metastatic HCC tend to be less prone to radioiodine-avidity. In general, the HCC clinical management follows the most recent ATA guidelines and National Comprehensive Cancer Network (NCCN) Thyroid Cancer guidelines (61, 62). Treatment options for recurrent HCC include radioiodine, radiofrequency ablation, ethanol ablation, external beam radiotherapy, and systemic treatment. Systemic treatment should be considered for patients with radiodine-refractory unresectable persistent, recurrent or metastatic disease. The options include tyrosine kinase inhibitors (TKIs),...
## TABLE 2  | Summary of the main RNA-associated silencing changes reported in Hurthle cell neoplasms.

| Sample size | Molecular alterations | Methods | Reference |
|-------------|----------------------|---------|-----------|
| 5 NTS, 5 HN | Upregulation of miR-31, miR-339, miR-183, miR-182, miR-181b, miR-221, miR-96, miR-182, miR-224 and miR-203 in HA versus NTS | Real-time quantitative polymerase chain reaction (RT-qPCR) | Nikiforov et al. (52) |
| 23 PTC, 9 FTC or HCC, 8 FA or HA, 4 ATC, 4 PDTC, 2 MTC | Upregulation of miR-31, miR-339, miR-183, miR-221 and miR-203 in HA versus hyperplastic tissue | TaqMan MicroRNA Reverse Transcription Kit and specific TaqMan miRNA assays | Petric et al. (56) |
| 39 HCC (22 non-metastatic and 17 with regional or distant metastases) | miR-138 and miR-768-3p downregulated in HCC compared with normal tissue (P = 0.013 and P = 0.010, respectively) and in tumors with metastases versus non-metastatic disease (P = 0.030 and P = 0.048, respectively) | TaqMan miRNA assay was miRNA array and RT-qPCR | Viens et al. (54) |
| 7 NTS, 14 HN, 15 FA, 20 PTC, 12 FTC, 20 HCC, 125 indeterminate (cytolology) | Only miR-125b overexpressed in FTC (P < 0.05) versus FA | PCR-Microarrays | Dettmer et al. (55) |
| 12 NTS, 13 oPTC, 72 WDTC | MALAT1 highly expressed in HCCs compared with FTC (n.s.) | In situ hybridization (ISH) and RT-qPCR | Covach et al. (57) |
| 25 FA, 25 HA, 24 HCC | miR-885 expressed in similar levels in FTCs and HCC | cDNA and miRNA microarrays and RT-qPCR | Jacques et al. (58) |
| 53 NTS, 10 WDT-UMP, 25 FA, 38 oFTC, 19 PTC | 13 genes with discriminatory capacity between tumors; - TP53, HOX9, RUNX1, MYD88, and CITED1 are implicated in tumorigenesis - MPRPL14, MRPS2, MRPS28, and COX6A1 are involved in mitochondrial metabolism - CalMki9Nalp and TPO are involved in thyroid metabolic pathways - TPO (FA), COX6A1, (HCC), MPRPL14, CITED1, and CalMki9Nalp (PTC) significantly overexpressed in tumors versus normal tissue - HOX9A under expressed in FAs and PTCs - MRPS2, MRPS28, and HOX9A upregulation in HCC versus FA and PTC | | |

NTS, normal thyroid specimens; HN, hyperplastic nodule; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; HCC, Hürthle cell carcinoma; FA, follicular adenoma; HA, Hürthle cell adenoma; ATC, anaplastic thyroid carcinoma; PDTC, poorly differentiated thyroid carcinoma; MTC, medullary thyroid carcinoma; MNG, multinodular goiter; NIFTP, non-invasive follicular thyroid neoplasm with papillary-like nuclear features; oPDTC, oncocytic poorly differentiated thyroid carcinoma; WDT-UMP, well-differentiated tumor of uncertain malignant potential; oFTC, oncocytic variant of follicular thyroid carcinoma.
such as levantinib and sorafenib, but despite the benefits shown in progression-free survival, they have not shown any improvements in overall survival (63, 64).

The promise of epigenetic alterations as therapeutic targets is that, unlike mutations, they can be potentially reversed. Azacitidine and decitabine are cytidine analogues, which inhibit DNA methyltransferase, were first synthesized in the early 1960s and were approved for the treatment of myelodysplastic syndromes. While their demethylating effect depends on incorporation of derived deoxy-azanucleotides into DNA, azacitidine-induced cytotoxicity is mainly due to incorporation into RNA in the cell cycle phase G1 at low drug concentrations, and to the incorporation into both RNA and DNA in the G1 and S phases of the cell cycle (65). Decitabine was shown to cause hypomethylation of DNA and intra-S-phase arrest of DNA replication, as its activity is exclusive to the incorporation into DNA of replicating cells (66). A phase 1 trial is currently assessing the ability of azacitidine to restore iodine uptake by dedifferentiated FTC and PTC, enabling detection and treatment with radioiodine in patients with metastatic disease, and will determine the efficacy of azacitidine in combination with radioiodine in this patient population. Interestingly, decitabine was shown to revert the TSH-R and NIS expression in human TC cell lines (67–69), having an inhibitory effect on the growth of undifferentiated TC cells (70). A phase 2 clinical trial assessing the effect of decitabine in patients with stage IV PTC and FTC unresponsive to radioiodine has completed recruitment and results are pending publication.

HDAC inhibitors have been studied in various tumor types and have shown promising results, particularly in hematological malignancies (71). Previous studies have showed that HDAC inhibitors could induce apoptosis and cell cycle arrest in ATC cell lines (72), and that these effects would likely be linked to an increase in the transcription of TP53, as well as to the modulation of cell cycle-related molecules (73–75). In addition, HDAC inhibitors, including depsipeptide and trichostatin, have effects on the reexpression of NIS, TPO and Tg genes, with an increased radioiodine uptake in PDTC and ATC cell lines, in vitro and in vivo (76, 77). The TSHR and NIS are key players in radioiodine-based treatment of differentiated thyroid cancers. Agostino et al. (78) performed the analysis of NIS and TSHR genes expression, and of the epigenetic control occurring at the gene promoter level after inhibition of RAS–BRAF–MAPK and PI3K–Akt–mTOR pathways in four human TC cell lines. The authors found that, in TC cells, MEK and Akt signaling pathways control post-/translational modifications of histones at specific genes, and these changes are noted even before the effects become more obvious in the proliferation rates. Recently, Wächter et al. (79) studied the cytotoxic effects of histone deacetylase inhibitors panobinostat, vorinostat (suberoylanilide hydroxamic acid (SAHA)), and trichostatin A in five TC cell lines, including PTC, FTC and ATC. All three compounds showed cytotoxic effect and a strong re-expression/over-expression of NIS transcript independently of the cell line. This recapitulates part of the results mentioned previously for poorly differentiated and anaplastic tumors (77), and supports the idea that the cell lines expressing low or absent NIS could be the most sensitive to deacetylase inhibitors. NIS expression could be modulated by the expression of miRNAs belonging to Let7 family (80). In the Watcher et al. study (79), treatment with these deacetylase inhibitors led to a stable expression or upregulation of H19, a long non-coding RNA highly expressed during tumorsgenesis in several tumors, including TC (81), in the tested TC cell lines. Interestingly, H19 had been shown to inhibit Insulin Receptor Substrate 1 (IRS-1), reducing cell viability, migration, and invasion in TC (82), which supports the thesis that H19 may have a tumor suppressor role in TC cells treated with deacetylase inhibitors, leading to differentiation and cell death (79). Finally, deacetylase inhibitors also led to the down-regulation of TTF1 transcripts, a thyroid transcription factor with oncogenic properties, in three cell lines. All these are relevant characteristics of deacetylase inhibitors for which clinical utility in patients with radioiodine refractory TC must be tested in clinical trials. Currently, there are phase 1 and 2 clinical trials using HDAC inhibitors such as romidepsin, belinostat, panobinostat and valproic acid in patients with TC, including limited cases of HCC, but the results are not encouraging (83–87).

Finally, although it is becoming evident that mi-RNAs play a role in the HCC pathogenesis, with an opportunity for a future as diagnose markers, there are still many unanswered questions on how they can contribute to the selective methylation or demethylation of TC genes. In what concerns treatment application, mi-RNAs are still far from being a druggable target, although it is possible that an acceleration of this pathway may be seen in the near future as RNA-based therapies are becoming an area of high investment, such is the case of the recent advances in the prevention area in vaccines. In vitro experiments by Vriens et al. (54), using a FTC cell line with overexpression of miR-100, miR-125b, and miR-138, found that the inhibition of the miRNAs by their targeted anti-mir led to cell growth arrest. On the other hand, the overexpression by pre-miRNAs (pre-miR-100, pre-miR-125b, and pre- miR-138) dramatically increased proliferation. This, and other pre-clinical reports, may pave the way for the next step into clinical trials, which has not yet started. As HCC are known for their mitochondrial DNA mutations and respiratory complex(es) metabolic disfunction, it would be very interesting to explore the potential treatment opportunities openned by the fact that miRNAs are translocated into mitochondria - thus modifying the expression of the mitochondrial genome. Likewise, the alterations in the mitochondrial DNA, which also contribute to epigenetic modifications of the nuclear DNA (88), could, at least in theory, be tackled in HCC.

**CONCLUSIONS**

Since Waddington’s introduction of epigenetics in the 1940s, there has been a significant development in the field and its application to cancer. The extension of these advances holds promises in establishing novel diagnostic and prognostic markers, with patient management implications, if not at the level of readily available systemic treatment options, certainly in the surgical and follow-up standards.

However, research on thyroid neoplasms has remained relatively limited by comparison with other cancers. One such case is the HCN,
which was endorsed by the 4th edition of the WHO Classification of Tumors. As one can see in this review, the evidence pertaining to the epigenomics of HCN is poor and inconsistent. In addition, a limitation in our review is that different referenced studies have used different morphological criteria to diagnose tumors falling into the spectrum of oncocytic follicular epithelial derived neoplasms, which are not necessarily follicular patterned-neoplasms, and therefore some of the epigenomics evidence trends may not always reflect a HCN histotype. This reinforces the need for determined and focused efforts in research and publication on the topic, taking into consideration the new pathological classification of HCN. Future advances in the research will allow the definition of diagnostic markers as well as specific guidelines towards a more personalized and effective treatment of HCN.

**AUTHOR CONTRIBUTIONS**

Conceptualization: SC, AL, VM. Writing – original draft: SC, AL, MP. Writing – review and editing: SC, AL, PS, VM. Supervising: VM. All authors contributed to the article and approved the submitted version.

**REFERENCES**

1. Canberk S, Lima AR, Correia M, Batista R, Soares P, Máximo V, et al. Oncocytic Thyroid Neoplasms: From Histology to Molecular Biology. Diagn Histopathol (2019) 25(5):154–65. doi: 10.1016/j.miphp.2019.02.002
2. DeLellis RA LR, Heitz PU, Eng C. Who Classification of Tumors. In: Pathology and Genetics of Tumors of Endocrine Organs, Vol. 2004. Lyon: IARC Press (2014).
3. Lloyd RV, Osmura RY, Klöppel G, Rosai J. Who Classification of Tumors of Endocrine Organs, 4th. Vol. 10. Lyon: IARC Press (2017).
4. Goffredo P, Roman SA, Sosa JA. Hurthle Cell Carcinoma. Cancer (2013) 119(3):504–11. doi: 10.1002/cncr.27770
5. Olinc B, Paunovic I, Loncar Z, Djukic V, Diklic V, Diklic A, Jovanovic M, et al. Survival and Prognostic Factors for Survival, Cancer Specific Survival and Disease Free Interval in 239 Patients With Hurthle Cell Carcinoma: A Single Center Experience. BMC Cancer (2017) 17(1):371. doi: 10.1186/s12885-017-3370-x
6. Petric R, Gazić B, Besic N. Prognostic Factors for Disease-Specific Survival in 108 Patients With Hurthle Cell Thyroid Carcinoma: A Single-Institution Experience. BMC Cancer (2014) 14(1):777. doi: 10.1186/1471-2407-14-777
7. Mills SC, Haq M, Smellie WJB, Harmer C. HRHill Cell Carcinoma of the Thyroid: Retrospective Review of 62 Patients Treated at the Royal Marsden Hospital Between 1946 and 2003. Eur J Surg Oncol (2009) 35(3):230–4. doi: 10.1016/j.ejso.2008.06.007
8. Waddington CH. The Epigenotype. 1942. Int J Epidemiol (2012) 41(1):10–3. doi: 10.1093/ije/dyr184
9. Catalano MG, Fortunati N, Boccuzzi G. Epigenetics Modifying Epigenetic Therapy. Front Endocrinol (Lausanne) (2012) 3:40. doi: 10.3389/fendo.2012.00040
10. Russo D, Damante G, Puxeddu E, Durante C, Filiatti S. Epigenetics of Thyroid Cancer and Novel Therapeutic Targets. J Mol Endocrinol (2011) 46(3):R73–81. doi: 10.1530/JME-10-0150
11. Kondo T, Asa SL, Ezzat S. Epigenetic Dysregulation in Thyroid Neoplasia. Endocrinol Metab Clin North Am (2008) 37(2):389–400. ix: doi: 10.1016/j.cencl.2007.12.002
12. Plass C, Pfister SM, Lindroth AM, Bogatyrrova O, Claus R, Lichter P. Mutations in Regulators of the Epigenome and Their Connections to Global Chromatin Patterns in Cancer. Nat Rev Genet (2013) 14(11):765–80. doi: 10.1038/nrg3554
13. Bird AP. DNA Methylation and the Frequency of CpG in Animal DNA. Nucleic Acids Res (1980) 8(7):1499–504. doi: 10.1093/nar/8.7.1499
14. Zafon C, Gil J, Perez-Gonzalez B, Jorda M. DNA Methylation in Thyroid Cancer. Endocr Relat Cancer (2019) 26(7):R415–R39. doi: 10.1530/ERC-19-0093
15. Jones PA. Functions of DNA Methylation: Islands, Start Sites, Gene Bodies and Beyond. Nat Rev Genet (2012) 13(7):484–92. doi: 10.1038/nrg3230
16. Baubec T, Schübeler D. Genomic Patterns and Context Specific Interpretation of DNA Methylation. Curr Opin Genet Dev (2014) 25:85–8. doi: 10.1016/j.gde.2013.11.015
17. Ting AH, McGarvey KM, Baylin SB. The Cancer Epigenome—Components and Functional Correlates. Genes Dev (2006) 20(23):3215–31. doi: 110.1101/gad.1464906
18. Swain JL, Stewart TA, Leder P. Parental Legacy Determines Methylation and Expression of an Autosomal Transgene: A Molecular Mechanism for Parental Imprinting. Cell (1987) 50(5):719–27. doi: 10.1016/0092-8674(87)90330-8
19. Mohandas T, Sparkes RS, Shapiro LJ. Reactivation of an Inactive Human X Chromosome: Evidence for X Inactivation by DNA Methylation. Science (1981) 211(4480):393–6. doi: 10.1126/science.6164095
21. Lee JS. Exploring Cancer Genomic Data From the Cancer Genome Atlas Project. JMB Rep (2016) 49(11):607–11. doi: 10.5483/BMB.Rep.2016.49.11.145
22. Moore LD, Le T, Fan G. DNA Methylation and Its Basic Function. Neuruphychopharmacology (2013) 38(1):23–38. doi: 10.1038/npp.2012.112
23. Cancer Genome Atlas Research N. Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell (2014) 159(3):676–90. doi: 10.1016/j.cell.2014.09.050
24. Galusca B, Dumollard JM, Lassandre S, Niveloux A, Prades JM, Estour B, et al. Global DNA Methylation Evaluation: Potential Complementary Marker in Differential Diagnosis of Thyroid Neoplasia. Virchows Arch (2005) 447(1):18–23. doi: 10.1007/s00428-005-1268-3
25. Park JI, Jeon S, Seo EH, Bae DH, Jeong YM, Kim Y, et al. Comprehensive DNA Methylation Profiling Identifies Novel Diagnostic Biomarkers for Thyroid Cancer. Thyroid (2020) 30(2):192–203. doi: 10.1089/thy.2019.0011
26. Bratt M, Loyo M, Rosenbaum E, Ostrow KL, Markova A, Papageakis S, et al. Correlation Between BRAF Mutation and Promoter Methylation of TIMP3, RASSF1A and RASSFIA in Thyroid Cancer. Epigenetics (2012) 7(7):710–9. doi: 10.4161/epi.20524

**FUNDING**

This work was financed by FEDER—Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 —Operacional Programme for Competitiveness and Internationalization (POCI), Portugal 2020, and by Portuguese funds through FCT - Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Inovação in the framework of the project “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274). Additional funding by the European Regional Development Fund (ERDF) through the Operational Programme for Competitiveness and Internationalization—COMPETE2020, and Portuguese national funds via FCT, under project POCI-01-0145-FEDER-016390; CANCEL STEM and from the FCT under the project POCI-01-0145-FEDER-031438: The other faces of telomerase: Looking beyond tumor immortalization (PTDC/MED_ONC/31438/2017). Additional funding through the Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo – Bolsa Edward Limbert MERCK/SPEDM 2019. SC is supported by FCT in the framework of a PhD grant (SFRH/BD/147650/2019).
26. Stephen JK, Chitale D, Narra V, Chen KM, Sawhney R, Worsham MJ. DNA Methylation in Thyroid Tumors in Pathogenesis. *Cancers (Basel)* (2011) 3(2):1732–43. doi: 10.3390/cancers3021732

27. Stephen JK, Chen KM, Merritt J, Chitale D, Divine G, Worsham MJ. Methylation Markers for Early Detection and Differentiation of Follicular Thyroid Cancer Subtypes. *Cancer Clin Oncol* (2015) 4(2):1–12. doi: 10.5539/ccv.v4n2p1

28. Bisarro Dos Reis M, Barros-Filho MC, Marchi FA, Beltrami CM, Kuasne H, Pinto CAL, et al. Prognostic Classifier Based on Genome-Wide DNA Methylation Profiling in Well-Differentiated Thyroid Tumors. *J Clin Endocrinol Metab* (2017) 102(11):4089–99. doi: 10.1210/jc.2017-00881

29. Ganly I, Makarov V, Deraje S, Dong Y, Reznik E, Seshan V, et al. Integrated Genomic Analysis of Hurthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. *Cancer Cell* (2018) 34(2):256–70 e5. doi: 10.1016/j.ccell.2018.07.002

30. Weber F, Aldred MA, Morrison CD, Plass C, Frilling A, Broelsch CE, et al. Silencing of the Maternally Imprinted Tumors Suppressor ARHI Contributes to Follicular Thyroid Carcinogenesis. *J Clin Endocrinol Metab* (2005) 90 (2):1149–55. doi: 10.1210/jc.2004-1447

31. Piyathilake CJ, Frost AR, Bell WC, Oelschlager D, Weiss H, Johanning GL, et al. Prognostic Classifiers in Advanced Thyroid Cancer: Comparison With Follicular Thyroid Carcinoma Compared With Its non-Hurthle Cell Counterpart. *Surgery* (2005) 138(6):1152–60. doi: 10.1016/j.surg.2005.08.034

32. PS Rippe C, Bagnes S, Cappiello A, et al. Evaluation of Global DNA Hypomethylation in Human Colon Cancer Tissues by Immunohistochemistry and Image Analysis. *Signal Transd Target Ther* (2019) 4:62. doi: 10.1038/s41392-019-0095-0

33. Xing M, Cohen Y, Mambo E, Tallini G, Udelsman R, Ladenson PW, et al. Early Occurrence of RASSF1A Hypermethylation and its Mutual Exclusion With BRAF Mutation in Thyroid Tumors. *Cancer Res* (2004) 64 (5):1664–8. doi: 10.1158/0008-5472.CAN-03-3242

34. Kouzarides T. Chromatin Modifications and Their Function. *Cell* (2007) 128 (4):693–705. doi: 10.1016/j.cell.2007.02.003

35. Chi P, Allis CD, Wang GD. Covalent Histone Modifications and Their Function. *Nat Rev Genet* (2007) 8:550–564. doi: 10.1038/nrg1976

36. Kondo T, Nakazawa T, Ma D, Niu D, Mochizuki K, Kawasaki T, et al. Epigenetic Silencing of TTF-1/NKX2-1 Through DNA Hypermethylation and Histone H3 Methylation in Thyroid Tumorsigenesis. *Endocr Pathol* (2008) 93(5):1600–8. doi: 10.1136/gut.2007-129658

37. Bucher P, Zimny-Arndt U, Gasser B, et al. MicroRNAs Regulate Histone Acetylation and Transcriptional Regulatory Mechanisms and Their Function. *Cell* (2012) 149(1):69–82. doi: 10.1016/j.cell.2012.02.007

38. Hsieh J, Bae YJ, de Capoa A, et al. Evaluation of Global DNA Hypomethylation in Human Colon Cancer Compared With Its non-Hurthle Cell Counterpart. *Surgery* (2005) 138(6):1152–60. doi: 10.1016/j.surg.2005.08.034

39. Granì G, Lamartina L, Durante C, Filiatti S, Cooper DS. Follicular Thyroid Cancer and Hurthle Cell Carcinoma: Challenges in Diagnosis, Treatment, and Clinical Management. *Lancet Diabetes Endocrinol* (2018) 6(6):500–14. doi: 10.1016/S2213-8587(17)30325-X

40. Petric R, Gacic B, Goricar K, Dolzan V, Druzd R, Besic N. Expression of miRNA and mRNA Expression in Follicular and Hurthle Cell Thyroid Neoplasms: Biological Significance and Diagnostic Utility. *J Clin Endocrinol Metab* (2014) 99(2):281–92. doi: 10.1210/jc.2014-2610

41. Canberk et al. Hurthle Cell Epigenomics

42. Marcucci G, Radmacher MD, Maharry K, Mrozek K, Ruppert AS, Paschka P, et al. MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia. *N Engl J Med* (2008) 358(18):1919–28. doi: 10.1056/NEJMoa074256

43. Esquela-Kersch et al. Slack Fj. Oncornirs - micro RNAs With a Role in Cancer. *Nat Rev Cancer* (2006) 6(4):259–69. doi: 10.1038/nrc1840

44. Lewis BP, Burge CB, Bartel DP. Conserved Seed Pairing, Often Flanked by Adenosines, Indicates That Thousands of Human Genes are MicroRNA Targets. *Cell* (2005) 120(1):15–20. doi: 10.1016/j.cell.2004.12.035

45. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA Expression Profiles Classify Human Tumors. *Nature* (2005) 435(7043):834–8. doi: 10.1038/nature03702

46. Marcucci G, Radmacher MD, Maharry K, Mrozek K, Ruppert AS, Paschka P, et al. MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia. *N Engl J Med* (2008) 358(18):1919–28. doi: 10.1056/NEJMoa074256

47. Li, Abdul-Mageed AB, Mondal D, Kandil E. MicroRNA Expression Profiles in Differentiated Thyroid Cancer, a Review. *Int J Clin Exp Med* (2013) 6 (1):74–80.

48. Hung CH, Chiu YC, Chen CH, Hu TH. MicroRNAs in Hepatocellular Carcinoma: Carcinogenesis, Progression, and Therapeutic Target. *BioMed Res Int* (2014) 2014:846804. doi: 10.1155/2014/846804

49. Hung CH, Chiu YC, Chen CH, Hu TH. MicroRNAs in Hepatocellular Carcinoma. *Nat Rev Cancer* (2006) 6(4):259–69. doi: 10.1038/nrc1840

50. de la Chapelle A, Jazdzewski K. MicroRNAs in Thyroid Cancer. *J Clin Endocrinol Metab* (2011) 96(11):3326–36. doi: 10.1210/jc.2011-1004

51. Hung CH, Chiu YC, Chen CH, Hu TH. MicroRNAs in Hepatocellular Carcinoma: Carcinogenesis, Progression, and Therapeutic Target. *BioMed Res Int* (2014) 2014:846804. doi: 10.1155/2014/846804

52. Nana-Sinkam SP, Croce CM. MicroRNA Regulation of Tumorsigenesis, Cancer Progression and Interpatient Heterogeneity: Towards Clinical Use. *Genome Biol* (2014) 15(9):445. doi: 10.1186/s13059-014-0445-8

53. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA Expression Profiling of Thyroid Tumors: Biological Significance and Diagnostic Utility. *J Clin Endocrinol Metab* (2008) 93(5):1600–8. doi: 10.1210/jc.2007-2696

54. Xing M, Cohen Y, Mambo E, Tallini G, Udelsman R, Ladenson PW, et al. Early Occurrence of RASSF1A Hypermethylation and its Mutual Exclusion With BRAF Mutation in Thyroid Tumors. *Cancer Res* (2004) 64 (5):1664–8. doi: 10.1158/0008-5472.CAN-03-3242

55. Petric R, Gacic B, Goricar K, Dolzan V, Druzd R, Besic N. Expression of miRNA and mRNA Expression in Follicular and Hurthle Cell Thyroid Neoplasms: Biological Significance and Diagnostic Utility. *J Clin Endocrinol Metab* (2014) 99(2):281–92. doi: 10.1210/jc.2014-2610

56. Lewis BP, Burge CB, Bartel DP. Conserved Seed Pairing, Often Flanked by Adenosines, Indicates That Thousands of Human Genes are MicroRNA Targets. *Cell* (2005) 120(1):15–20. doi: 10.1016/j.cell.2004.12.035

57. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA Expression Profiles Classify Human Tumors. *Nature* (2005) 435(7043):834–8. doi: 10.1038/nature03702
66. Yang X, Lay F, Han H, Jones PA. Targeting DNA Methylation for Epigenetic Therapy. *Trends Pharmacol Sci* (2010) 31(11):536–46. doi: 10.1016/j.tips.2010.08.001

67. Provenzano MJ, Fitzgerald MP, Krager K, Domann FE. Increased Iodine Uptake in Thyroid Carcinoma After Treatment With Sodium Butyrate and Decitabine (5-Aza-Dc). *Otolaryngol Head Neck Surg* (2007) 137(5):722–8. doi: 10.1016/j.otohns.2007.07.030

68. Venkataraman GM, Yatin M, Marcinek R, Ain KB. Restoration of Iodide Uptake in Dedifferentiated Thyroid Carcinoma: Role of Epigenetics. *J Mol Endocrinol* (2014) 52(2):121–31. doi: 10.1530/JME-13-0160

69. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, et al. A Genomic Screen for Genes Upregulated by Demethylation and Histone Deacetylation Inhibition in Human Colorectal Cancer. *Nat Genet* (2002) 31(2):141–9. doi: 10.1038/ng892

70. Miasaki FY, Vivaldi A, Ciampi R, Agate L, Collecchi P, Capodanno A, et al. Role of Epigenetics. *Clin Cancer Res* (2007) 13(4):315–25. doi: 10.1158/1078-0432.CCR-06-2776

71. Imanishi R, Ohtsuru A, Ishimatsu M, Isoka T, Namba H, Seto S, et al. A Histone Deacetylase Inhibitor Enhances Killing of Undifferentiated Thyroid Carcinoma Cells by p53 Gene Therapy. *J Clin Endocrinol Metab* (2002) 87(10):4821–4. doi: 10.1210/jc.2002-020877

72. Kitazono M, Bates S, Fok P, Fojo T, Blagosklonny MV. The Histone Deacetylase Inhibitor FR901228 (Desipramine) Restores Expression and Function of the p53 Tumor Suppressor in Human Colorectal Cancer Cells. *Clin Exp Metastasis* (2001) 19(1):111–7. doi: 10.1023/A:1017446017544

73. Mitsiades CS, Poulaki V, McMullan C, Negri J, Fanourakis G, Goudopoulou A, et al. Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid Cancer. *Cancer Res* (2005) 11(10):3958–65. doi: 10.1118/1078-0432.CCR-03-07-0776

74. Kitazono M, Robey R, Zhan Z, Sarlis NJ, Skarulis MC, Aikou T, et al. Low Concentrations of the Histone Deacetylase Inhibitor, Desipramine (FR901228), Increase Expression of the Na(+)l(+) Symporter and Iodide Accumulation in Poorly Differentiated Thyroid Carcinoma Cells. *J Clin Endocrinol Metab* (2001) 86(7):3430–5. doi: 10.1210/jcem.86.7.621

75. Furuya F, Shimura H, Suzuki H, Yaki K, Ohts K, Haraguchi K, et al. Histone Deacetylase Inhibitors Restore Radioidine Uptake and Retention in Poorly Differentiated and Anaplastic Thyroid Cancer Cells by Expression of the Sodium/Iodide Symporter Thyroperoxidase and Thyroglobulin. *Endocrinology* (2004) 145(6):2865–75. doi: 10.1210/en.2003-1258

76. D’Agostino M, Sponzillo M, Puppin C, Celano M, Maggiano V, Baldan F, et al. Different Expression of TSH Receptor and NIS Genes in Thyroid Cancer: Role of Epigenetics. *J Mol Endocrinol* (2014) 52(2):121–31. doi: 10.1530/JME-13-0160

77. Furuya F, Shimura H, Suzuki H, Yaki K, Ohts K, Haraguchi K, et al. Histone Deacetylase Inhibitors Restore Radioidine Uptake and Retention in Poorly Differentiated and Anaplastic Thyroid Cancer Cells by Expression of the Sodium/Iodide Symporter Thyroperoxidase and Thyroglobulin. *Endocrinology* (2004) 145(6):2865–75. doi: 10.1210/en.2003-1258

78. D’Agostino M, Sponzillo M, Puppin C, Celano M, Maggiano V, Baldan F, et al. Different Expression of TSH Receptor and NIS Genes in Thyroid Cancer: Role of Epigenetics. *J Mol Endocrinol* (2014) 52(2):121–31. doi: 10.1530/JME-13-0160

79. Wachter S, Damanakis AI, Elsalt M, Roth S, Wunderlich A, Verburg FA, et al. Epigenetic Modifications in Thyroid Cancer Cells Restore NIS and Radioidine Uptake and Promote Cell Death. *J Clin Med* (2018) 7(4):61. doi: 10.3390/jcm7040061

80. Damanakis AI, Eckhardt S, Wunderlich A, Roth S, Wissniewski TT, Bartsch DK, et al. MicroRNAs Let7 Expression in Thyroid Cancer: Correlation With Their Deputed Targets HMG2A and SLCSA5. *J Clin Endocrinol Metab* (2016) 124(6):1213–20. doi: 10.1077/s00432-016-2138-2

81. Raveh E, Matouk IJ, Gilson M, Hochberg A. The H19 Long Non-Coding RNA in Cancer Initiation, Progression and Metastasis - a Proposed Unifying Theory. *Mol Cancer* (2015) 14:184. doi: 10.1186/s12943-015-0458-2

82. Wang P, Liu G, Xu W, Liu H, Bu Q, Sun D. Long Noncoding Rna H19 Inhibits Cell Viability, Migration, and Invasion Via Downregulation of IRS-1 in Thyroid Cancer Cells. *Technol Cancer Res Treat* (2017) 16(11):112–12. doi: 10.1177/1533034617733904

83. Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA, et al. Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients With Metastatic Radiiodine-Refractory Thyroid Carcinoma. *J Clin Endocrinol Metab* (2009) 94(1):164–70. doi: 10.1205/jc.2008.1631

84. Sherman EJ, Su YB, Lyall H, Schöder H, Fyfe MG, Ghossein RA, et al. Evaluation of Romidepsin for Clinical Activity and Radiodine Reuptake in Radioactive Iodine-Refractory Thyroid Carcinoma. *Thyroid: Off J Am Thyroid Assoc* (2013) 23(5):593–9. doi: 10.1089/thy.2012.0393

85. Catalano MG, Pugliese M, Gargantini E, Grange C, Bussolati B, Ascoli S, et al. Cytotoxic Activity of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Anaplastic Thyroid Cancer In Vitro and In Vivo. *Int J Cancer* (2012) 130(3):694–704. doi: 10.1002/ijc.26057

86. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. Valproic Acid as Epigenetic Cancer Drug: Preclinical, Clinical and Transcriptional Effects on Solid Tumors. *Cancer Treat Rev* (2008) 34(3):206–22. doi: 10.1016/j.ctrv.2007.11.003

87. Nihoul F, Merkel R, Yang L, Patel D, Reynolds JC, Sadowski SM, et al. A Phase II Trial of Valproic Acid in Patients With Advanced, Radiiodine-Resistant Thyroid Cancers of Follicular Cell Origin. *Clin Endocrinol (Oxf)* (2017) 86(1):128–33. doi: 10.1111/cen.13154

88. Xie CH, Naito A, Mizumachi T, Evans TT, Douglas MG, Cooney CA, et al. Mitochondrial Regulation of Cancer Associated Nuclear DNA Methylation. *Biochem Biophys Res Commun* (2007) 354(3):656–61. doi: 10.1016/j.bbrc.2007.10.047

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.